Nicolay, Jan P.
Thorn, Verena
Daniel, Christoph http://orcid.org/0000-0002-6803-4755
Amann, Kerstin
Siraskar, Balasaheb
Lang, Florian http://orcid.org/0000-0003-2962-1540
Hillgruber, Carina
Goerge, Tobias
Hoffmann, Stefan http://orcid.org/0000-0002-1959-1686
Gorzelanny, Christian
Huck, Volker http://orcid.org/0000-0001-8988-1091
Mess, Christian
Obser, Tobias
Schneppenheim, Reinhard
Fleming, Ingrid http://orcid.org/0000-0003-1881-3635
Schneider, Matthias F.
Schneider, Stefan W.
Funding for this research was provided by:
Helmholtz-Gemeinschaft (Helmholtz-Alliance on Immunotherapy of Cancer program)
Deutsche Forschungsgemeinschaft (SFB/Transregio 23 SWS TPA9, SFB/Transregio 23 SWS TPA9, SHENC – Research Unit FOR 1543 VH/SWS A2, SHENC – Research Unit FOR 1543 UB/RS A1, SHENC – Research Unit FOR 1543 UB/RS A1, SFB/Transregio 23 IF TPA6, SHENC – Research Unit FOR 1543 VH/SWS A2, SFB/Transregio 23 SWS TPA9, SHENC – Research Unit FOR 1543 VH/SWS A2)
Article History
Received: 21 June 2017
Accepted: 1 July 2018
First Online: 19 July 2018
Competing Interests
: J.P.N. received travel and congress participation funding from TEVA as well as consulting fees from TEVA, Novartis, Innate Pharma and Biogen.